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Abstract
Obesity plays relevant pathophysiological role in the 
development of health problems, arising as result 
of complex interaction of genetic, nutritional, and 
metabolic factors. Due to the role of adipose tissue 
in lipid and glucose metabolism, and low grade 
inflammation, it is necessary to classify obesity on the 
basis of body fat composition and distribution, rather 
than the simply increase of body weight, and the Body 
Mass Index. The new term of adiposopathy (‘‘sick 
fat’’) clearly defines the pathogenic role of adipose 
tissue. Four phenotypes of obese individuals have 
been described: (1) normal weight obese (NWO); (2) 
metabolically obese normal weight; (3) metabolically 
healthy obese; and (4) metabolically unhealthy obese 
or “at risk” obese. Moreover, sarcopenic obesity has 
been related to all the phenotypes. The category of 
normal weight lean, represented by metabolically 
healthy normal weight has been classified to distinguish 
from NWO. It is crucial to recommend a bariatric 
surgery taking into account adiposopathy and sick fat 
that occurs with the expansion of fat mass, changing 
the inflammatory and metabolic profile of the patient. 
Body fat percentage and genetic polymorphism have to 
be evaluated to personalize the best bariatric surgery 
intervention.
Key words: Obesity; Adiposopathy; Normal weight 
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major regulators of adipose tissue metabolism[10].
Therefore, the greatest limitation of any measure 
that relegates the diagnosis of obesity to the mere 
quantity of weight and circumference gain, without 
taking into account the body composition, in terms of 
body fat increase and body lean decrease, is the failure 
to consider the impact of adiposity on physiological and 
metabolic processes that result in increased morbidity 
and mortality[11].
Due to the endocrine and inflammatory role of 
the adipose tissue it is necessary to classify obesity 
condition on the basis of body fat composition and 
distribution, rather than simply on the increase of body 
weight (Figure 1). Therefore, the body mass index 
(BMI), a ratio between weight to the squared height 
(kg/m2) of a subject, used to easily approximate body 
fat percentage and stratify people into categories, 
leads to a large error and misclassification.
According to BMI, general population is classified 
in five categories: underweight (BMI < 18.5 kg/m2), 
normal weight (BMI 18.5-24.9 kg/m2), class Ⅰ obesity 
- overweight (BMI 25.0-29.9 kg/m2), class Ⅱ obesity 
- obesity (BMI 30.0-39.9 kg/m2), class Ⅲ obesity - 
extreme obesity (BMI > 40 kg/m2).
The currently used BMI cut-off values for pre-obesity 
and obesity are based on morbidity and mortality 
studies in relation to Caucasian population[8-10]. 
However, there is a controversy in the literature, 
termed the “obesity paradox”, which associates 
better survival and fewer cardiovascular events in 
patients with mildly elevated BMI afflicted with chronic 
diseases[11].
In fact, the outdated BMI formula developed nearly 
200 years ago by Quetelet, is not a measurement 
of adiposity, but merely an imprecise mathematical 
estimate[12-14].
Its popularity stems in part from its convenience, 
safety, and minimal cost, and its use is widespread, 
despite the fact, BMI ignores several important factors 
affecting adiposity. Moreover, the error in the diagnosis 
of obesity generates important effects on health care 
costs. 
BMI formula is only an arithmetic approximation for 
the relative quantity of adiposity and is used to predict 
and evaluate disease risk in epidemiological studies, 
thereby acting only as a population-level indicator of 
obesity.
Because BMI does not measure PBF directly and 
poorly distinguishes between total body fat and total 
body lean, or bone mass, the use of BMI as an index 
of PBF for a person may be inaccurate and not useful 
as a cardiovascular risk factor[15-17].
However, according to a WHO expert committee, 
“there is no agreement about cut-off points for the PBF 
that constitutes obesity”[10]. 
Current research suggests that the obesity cut-off 
points of PBF are in the 23%-25% range in men and 
30%-35% range in women[18].
The clinical use of WHO BMI cut-off values when 
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Core tip: Obesity is a global public health problem 
due to its association with several diseases and 
reduced lifespan, as result of complex interaction of 
genetic, nutritional, and metabolic factors. The term 
of adiposopathy clearly defines the pathogenic role 
of adipose tissue. Four phenotypes of obesity have 
been described, based on body fat composition and 
distribution: (1) normal weight obese; (2) metabolically 
obese normal weight; (3) metabolically healthy obese; 
and (4) metabolically unhealthy obese. Sarcopenic 
obesity has been characterized, related to all the 
described phenotypes. Body fat percentage and genetic 
polymorphism have to be evaluated to personalize the 
best bariatric surgery intervention.
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BODY COMPOSITION STUDY AS A NEW 
WAY TO CLASSIFY SUBJECT
The American Medical Association’s Council on Science 
and Public Health Report 4, has identified the following 
common criteria to define a disease as: (1) an impair­
ment of the normal functioning of some aspect of the 
body; (2) characteristic signs or symptoms; and (3) 
harm or morbidity[1].
The World Health Organization (WHO) defines 
obesity as “a condition in which percentage body fat 
(PBF) is increased to an extent in which health and 
well-being are impaired, and, due to the alarming pre-
valence increase, declared it as a “global epidemic”[2].
The high prevalence of obesity is a global public 
health problem due to its association with several 
diseases[3,4], and reduced lifespan[5]. It arise as a result 
of complex interaction of genetic, life style, dietary 
habitus, energy expenditure, nutritional and metabolic 
factors, as the adipocyte metabolism[6,7]. 
The shared definition that the adipose tissue 
and skeletal muscle are an energy storage has been 
replaced by the notion that these tissues have a role in 
lipid and glucose metabolism due to the large number 
of bioactive proteins, termed adipokines and myokines 
produced[8], that are related to some cardiovascular 
risk factors influences of obesity[9].
Moreover, obesity and glucose metabolism are 
intimately related to low grade systemic inflammation, 
involving a number of pro-inflammatory cytokines 
produced by many cell types that also appear to be 
applied to the Italian population cause misclassi-
fications, and a considerable number of subjects, both 
males and females, will not be classified as obese 
based on their BMI alone[19].
The disagreement became impressive in the 
classification of obese women: in the class of age 
30-40 the proportion of obese women according to 
BMI is 30% reaching about 82% if the classification 
is based on PBF. Notably, among women that were 
classified as normal according to their observed PBF, 
the median BMI was 20.1, ranging from 15.6 to 26.7.
For the Italian population, the percentage of obese 
women according to PBF classification increases as age 
increases, ranging from 63.17% in women younger 
than 20 years to 87.39% in women older than 60[20].
Moreover, values corresponding to normal weight, 
overweight, and various subgroups of obesity are 
confounded by body frame and muscularity, fluid 
retention, sarcopenia in aging or disease, spinal 
deformities, physical disabilities, and transcultural 
differences. A person with the same BMI, may have a 
large proportion of total body fat mass and be obese, 
or may have a considerable muscle mass and be a 
weight-lifter. Moreover, PBF at a given BMI will tend to 
vary across gender, age, and race-ethnicity[21-23]. 
Moreover, it is recommended to measure waist 
circumference (WC) in adults with BMIs below 35 
kg/m2, to further assess disease risk[24].
Anyway, obese individuals differ not only in the 
amount of excess fat mass, but also in the regional 
distribution of the fat within the body. The fat distri-
bution affects the risk associated with obesity. It is 
useful therefore, to be able to distinguish between 
those at increased risk as a result of abnormal fat 
distribution or android obesity from those with the less 
serious gynoid fat distribution, in which fat is more 
evenly and peripherally distributed around the body[2].
On the hand even if there are some obese people 
are prone to develop alterations in fat distribution 
and metabolic disease, others are protected from the 
adverse metabolic effects of weight gain and increased 
adiposity[25].
Some studies suggested that the main issue to 
explain the metabolic abnormalities in normal weight 
individuals was fat distribution. 
Certain attributes of visceral fat, the adipose 
tissue surrounding abdominal organs, make its accu-
mulation more worrisome than the accumulation of 
subcutaneous fat, which resides below the skin[26-28].
Other markers for excess body fat evaluation have 
to be used in clinical practice and investigation (e.g., 
WC, skin fold thickness, waist-to-hip ratio, waist-to-
height ratio). 
WC or waist-to-hip ratio has been used as a proxy 
measure for body fat distribution when investigating 
the health risk increased with an increasing ratio. 
Some studies have suggested that WC, either singly 
or in combination with BMI, may have a stronger 
relation to some health outcomes than BMI alone[29]. 
Moreover, progressively higher values of BMI and WC 
are associated with a progressive elevation in metabolic 
markers of cardiovascular disease (CVD) risk such as 
total serum cholesterol, triglycerides, blood glucose 
and a progressive reduction of HDL-cholesterol, with 
a clear-cut increase in the incidence of all-cause and 
cardiovascular deaths as well as of cardiovascular 
morbid and fatal events[30]. In post-menopausal women, 
it was reported that both BMI and WC were associated 
with mortality, but WC may be more important than 
BMI[31], as it reflects abdominal fat levels. In the 
Nurses’ Health Study, waist-to-hip ratio and WC were 
also independently strongly associated with increased 
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Figure 1  Techniques in body composition.
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as “fat mass disease”[38]. Different adverse physical 
and metabolic health consequences could occur as 
directed or undirected consequences of adipose tissue 
mass spread and dysfunction[39], such as metabolic 
syndrome (MS), respiratory disorders, joint pain, 
diabetic retinopathy, low self-esteem, cardiovascular, 
neurologic, pulmonary, musculoskeletal, dermatologic, 
gastrointestinal, genitourinary, renal and psychological 
diseases and cancer[3,4,40-42]. Moreover, also a slight 
rise of body weight may represent a risk factor for 
the onset of metabolic abnormalities that lead to 
development metabolic disease[43].
According to Patel and Abate[44], the subcutaneous 
adipose tissue (SAT) can be a major contributor of 
systemic free fatty acid flux, more than visceral or 
retroperitoneal fat, able to determine the insulin resi-
stance development.
Apovian et al[45] explained the insulin resistance and 
vascular endothelial dysfunction in obese subjects with 
the phenomenon of adipose tissue macrophage (ATM) 
infiltration, in the form of crown-like structures, asso-
ciated with and elevated plasma high sensitivity C-reactive 
protein (hs-CRP) levels. 
Because of the complexity of the obesity condition, 
it is clear that we need a new and more adequate 
model, possibly based on findings at the physiopa-
thological level and a new method to correctly identify 
all the affected subjects for an efficient and successful 
treatment. 
If Bays et al[39] affirmed that to deny the adipo-
sopathy, also in mildly overweight patients, represents 
denying the opportunity of cure to this individuals, and 
perhaps to entire populations, we added the importance 
to evaluate PBF in normal weight individuals to predict 
in advance the risk of adiposopathy, and to verify the 
real state of health.
ECTOPIC FAT DISTRIBUTION AND 
ORGAN FUNCTION
The association between visceral fat and metabolic and 
cardiovascular disorders is also related to accumulation 
of ectopic fat that accompanies visceral adiposity[46]. 
Moreover, the hepatic fat observed in patients with 
insulin resistance could be independent from the visceral 
fat content[47].
Healthy expansion of subcutaneous fat in response 
to obesity is accompanied by enlargement of fat mass 
through enhanced recruitment of preadipocytes along 
with adequate vascularization of expanding adipose 
tissue and minimal fibrosis and minimal infiltration of 
inflammatory ATMs. In contrast, pathologic expansion 
is associated with rapid growth of fat tissue through 
the enlargement of existing adipocytes and inadequate 
vascularization leading to fibrosis and inflammatory 
ATM infiltration that secrete high levels of inflammatory 
cytokines[48]. 
This pathologic expansion is associated with adipose 
risk of coronary heart disease among women with 
a BMI of < 25 kg/m2[32]. WC reflects abdominal or 
intra-abdominal fat, and hip circumference reflects 
different aspects of body composition in the gluteo-
femoral region, i.e., muscle mass, bone, and fat mass. 
The importance of waist and hip measurements, and 
the waist to hip ratio, lies in the apparently different 
physical and metabolic characteristics of these two 
regions, and therefore the diverse clinical outcomes 
in subjects with a gynoid (low waist to hip ratio, lower 
body obesity) or android (high waist to hip ratio, 
upper body obesity) body conformation. This may 
be due to the tendency for abdominal adipocytes 
to enlarge (hypertrophy) whereas subcutaneous 
femoral adipocytes increase in number (hyperplasia), 
perhaps due to increased levels of the adipogenic 
transcription factors CCAAT/ enhancer-binding protein 
α (C/EBPα; GeneBank accession No: NC_000019) and 
peroxisome proliferator-activated receptor-γ2 (PPARγ2; 
GeneBank accession No: NC_000003) in hypertrophic 
adipocytes[33]. Hypertrophic adipocytes tend to be 
associated with dyslipidemia and insulin resistance[34]. 
It has been suggested that the composition of gluteal 
fat deposits correspond more closely with that of 
visceral deposits rather than femoral deposits[35]. 
In conclusion, diagnosis, therapy and follow up of 
all subtypes of obesity must not be based on “body 
weight” parameter, but body composition parameters 
and energetic expenditure are required. 
To overcome misclassifications, direct measure-
ments of PBF, by magnetic resonance imaging (MRI), 
computerized tomography (CT), dual energy X-ray 
absorptiometry (DXA), bioimpedence analysis, total 
body water or hydrometry, and skinfold thickness would 
be a better tool for diagnosing the obese phenotypes 
(Figure 1). 
OBESITY AS DISEASE: SICk FAT OR FAT 
MASS DISEASE
Bays et al[36] have coined a new term that well defines 
the concept of “sick fat”, the adiposopathy, in order 
to highlight the pathogenic role of adipose tissue. The 
adiposopathy is caused by positive caloric balance, 
that occurred in hypercaloric diet and sedentary 
lifestyle in genetically predisposed and environmentally 
sensitive individual[36]. Impaired adipocyte proliferation 
or differentiation (adipogenesis), visceral adiposity, 
growth of adipose tissue beyond adequate vascular 
supply and ectopic fat deposition are anatomical 
manifestations of adiposopathy that are associated 
with adverse endocrine and immune responses leading 
to metabolic disease[37,38].
In order to understand the importance of the 
role of adipose tissue in the onset of a pathological 
condition and distinguish the degree and type of 
disease, we agree with the definition proposed by 
Bays of adiposopathy, as “sick fat disease”, and obesity 
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tissue accumulation in ectopic locations such as liver, 
skeletal muscle, and pancreas as well as visceral 
adiposity[49].
The existence of “metabolically healthy obese 
(MHO)”[50,51] further supports this concept as these 
individuals have less ectopic fat despite high amount 
of subcutaneous fat in gluteal depot and are insulin 
sensitive[51].
Therefore, adipose tissue distribution is a more 
significant predictor of metabolic and cardiovascular risk 
than overall adiposity. Inability to expand subcutaneous 
depots in response to positive energy balance[52] results 
in metabolic and cardiovascular complications.
IMPACT OF CROSS TALk
Adipose tissue, found in several locations throughout 
the body and long thought to be primarily a repository 
for triglycerides, is also important for regulating 
metabolism and body’s physiologic. Fat is an endocrine 
tissue and, indeed, may constitute the largest endocrine 
organ in the body[53,54].
If in the past, adipose tissue was considered to be 
a metabolically inactive fat depot, the current view 
of adipose tissue is that of an active secretory organ, 
sending out and responding to signals that modulate 
appetite, energy expenditure, insulin sensitivity, 
endocrine and reproductive systems, bone metabolism, 
and inflammation and immunity[55]. 
Expansion of the adipose tissue is accompanied by 
an increased infiltration of immune cells, in particular 
macrophages and T-cells[56], with a pro-inflammatory 
phenotype. The “cross-talk” between the infiltrating 
cells and the tissue-resident adipocytes leads to 
secretion of adipokines, cytokines, chemokines, and 
lipids with a predominant proinflammatory character[57]. 
Several indirect lines of evidence suggest that fatty 
acids can modulate the immune response. One of these 
is that levels of several fatty acids are associated with 
levels of inflammatory markers in healthy individuals[58].
More directly, the type of fatty acids contained in 
the diet has been suggested to influence the risk of 
development of inflammatory diseases in which the 
immune system plays an important role.
This cross-talk has an also been shown to affect 
the function of adipocytes, such as lipolysis, which will 
most likely result in altered concentration of circulating 
free fatty acids.
Some of obesity phenotypes are associated with 
a high risk of developing diabetes type 2 (T2DM) 
however for a given adiposity, there is a large hetero-
geneity in the metabolic risk mainly linked to the 
location of excessive adipose tissue. 
The cause of glucose, lipid, or atherogenic disorders 
can be found in the visceral adipose tissue (VAT), 
representing a predictive factor for those disorders[59]. 
The role of visceral fat in the development of 
peripheral insulin resistance in T2DM is related to 
the insulin-mediated glucose uptake[60], that can be 
directly affected by inflammatory cytokines, like tumor 
necrosis factor alpha (TNF-α), transforming growth 
factor beta (TGF-β), and interleukin 6 (IL-6) secreted 
by visceral fat depot.
Moreover, it has been demonstrated that both 
hepatic fat accumulation than hepatic insulin resistance 
are related to visceral fat depots, representing 
approximately 20% of total body fat mass in men and 
6% in women[61], as approximately 80% of hepatic 
blood supply is derived from the portal vein[62].
Due to the interactions within adipose tissue and 
muscle, involved in the endocrine bi-directional “cross-
talk” between these tissues[63], it was observed a loss 
of muscle strength, that depends on both decrease 
in muscle mass and accumulation of inter-muscular 
adipose tissue, contributing to the decline of muscle 
quality[64]. Therefore, the evaluation of body lean mass, 
together with body fat mass analysis and body force 
assessment, could contribute to predict sarcopenic 
obesity risk.
INFLAMMATION AND THE ROLE 
OF GENETIC vARIATIONS OF 
INFLAMMATORY TRIAD CYTOkINES 
IN OBESITY RELATED CHRONIC-
DEGENERATIvE DISEASES
The obese state is a low­grade systemic inflammation, 
characterized by abnormal adipokine production, 
and activation of some pro-inflammatory signalling 
pathways, resulting in the induction of several 
biological markers of inflammation. In fact, inflam-
matory markers, such as C-reactive protein (CRP), 
IL-6, IL-1 family [IL-1α, IL-1β and IL-1 receptor 
antagonist (IL-1Ra)] and TNF-α are increased in obese 
individuals compared with lean subjects, although not 
to the same extent observed in classic inflammatory 
conditions[65].
Though all the functional consequences of the 
increase in inflammatory processes in obese are 
not yet known, is an established fact that cytokines 
have metabolic activities, as many “adipokines” 
can modulate of both the metabolic and vascular 
homeostasis[66], acting not only as autocrine/paracrine 
regulators, but also reaching, from the perivascular 
fat depot, the surrounding target organs, through the 
systemic circulation (“outside-to-inside” cellular cross-
talk)[67-69]. 
This inflammatory mechanism is the basis of the 
increased risk of development of T2DM, acute heart 
attacks and Alzheimer’s disease[70,71] in obesity.
Polymorphisms and allele variants of cytokines 
genes are presumed to be involved in obesity and 
related chronic-degenerative diseases, therefore an 
understanding of their food association could be useful 
for nutritional pre-emption.
The practical application of predictive and preventive 
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medicine requires early identification of the individuals 
who are on a path toward earlier development of 
disease, followed by the introduction of a targeted 
intervention. Ideally, one could use the identification 
of specific polymorphisms, an early marker of disease 
susceptibility, to prevent complications of disease by 
the use of nutritional agents that modulate the biology 
resulting from the genetic variation.
A high degree of sequence variation recently has 
been shown to exist in cytokine genes. These gene 
polymorphisms are relatively common in regulatory 
regions of the cytokine genes and therefore may be 
functionally significant in defining inter-individual 
differences in transcription or post-transcriptional 
processes. These genetic variations therefore provide 
a potential mechanism by which individuals may have 
different degrees of response to the same stimulus.
Among the first genes activated with any injurious 
challenge are the genes for IL-6, IL-1 and TNF-α. 
These molecules activate each other and both are 
critical components of the inflammatory process.
IL-6
Besides regulating the immune system, IL-6 also 
plays a role in the regulation of body fat and energy 
expenditure. Recent studies have shown that IL-6 
deficient mice develop mature onset obesity with high 
leptin levels in the circulation[28].
Moreover, intracerebroventricular IL-6 treatment 
decreases body fat and increases energy expenditure 
in rodents[72].
In humans, high cytokine levels (including IL-6) and 
cytokine brain synthesis were found to increase resting 
energy expenditure and induce cachexia. Additionally, 
a subcutaneous injection of IL-6 increased resting 
metabolic rate and hypothalamic-pituitary-adrenal axis 
activity in a dose-dependent fashion, suggesting that 
hypothalamic corticotrophin-releasing hormone may 
mediate both of these actions in humans. A second 
possibility by which IL-6 may affect energy expenditure 
is enhanced adrenergic stimulation. In the other hand, 
high circulating IL-6 concentrations have been found 
to predict the development of type 2 diabetes[73,74]. 
IL-6 has a central role in the mechanism of pro-
inflammation pathway and there are some evidences 
suggesting the implication of a network of cytokines 
for the development of metabolic disorders, as type 2 
diabetes, CVD, and sarcopenia. 
Polymorphisms that affect the gene transcription 
and production of IL-6, like the gene promoter -174 
G/C polymorphism, are examples of genetically deter-
mined-changes in metabolism and energy homeostasis. 
In fact, IL-6 gene promoter polymorphism -174 G/C 
is shown to influence IL-6 transcription as well as 
overweight and insulin sensitivity. 
Data suggest that endogenous IL-6 has effects 
on energy expenditure but upper endogenous IL-6 
production, e.g., due to the presence of allele C of 
-174G/C polymorphism, contributes to obesity in 
humans and related pathologies and is a disadvantage 
for longevity.
TNF-α
Macrophages, whose adipose tissue is composed, 
are the major source of TNF-α produced by the white 
adipose tissue and contribute approximately 50% of 
white adipose tissue-derived IL-6[75].
TNF-α participates to inflammatory events but it’s also 
an important autocrine/paracrine of fat cell function 
which limits adipose tissue and skeletal muscle 
expansion, by inducing lipolysis[76], insulin resistance[77], 
and muscle apoptosis[78]. Its presence also results in 
an increase in circulating leptin concentrations[79] and, 
finally, its overexpression, by exceeding fat, aimed at 
stopping the growth of tissues[80].
Several population-based studies have suggested 
an association between TNF-α polymorphisms and 
obesity-related phenotypes[81].
TNF-α has a direct (possibly paracrine) function in 
adipose tissue where it limits its mass by stimulating 
lipolysis and decreasing lipoprotein lipase expression 
and activity, that means it’s involved in the adipostatic 
function[76].
TNF-α can induce hyperlipidemia and insulin 
resistance, especially in presence of single nucleotide 
polymorphisms (SNPs) on the promoter (-308 G/A and 
-238 G/A)[82].
In fact, TNF-α is an antagonist of insulin receptor 
and an overproduction could impair insulin signalling 
as well as down-regulate adipose lipase producing 
hyperlipidemia. Levels of TNF-α are high in an obese 
population and moreover experiments in vitro show 
that allele A alters binding of nuclear factors to the -308 
region causing a general increase in transcriptional[83]. 
Interestingly, cases with the -308 A allele of the TNF-α 
gene have significantly higher hip and WC, BMI and 
body fat mass values than obese individuals carrying 
the -308 G allele, but not the waist-to-hip ratio[84].
An higher fasting insulin levels, higher Homeostasis 
Model Assessment of Insulin Resistance (HOMA-IR), 
higher systolic blood pressure and lower HDL cholesterol 
were highlighted among -308 A allele TNF-α obese 
carriers than -308 G obese carriers, and overweight 
subjects with impaired glucose tolerance showing a 
genotype have higher risk of developing T2DM than 
subjects without this genotype[85].
This observation is consistent with previous findings, 
suggesting that leptin secretion and insulin resistance 
are affected by TNF-α expression. Disturbances in 
circulating levels of leptin may be accompanied by a 
lower control of appetite and thermogenesis or may 
occur as a consequence of leptin resistance.
IL-1
Other intriguing molecules produced by adipose tissue 
and involved in metabolism are that belonging to 
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the class of IL-1. IL-1 biological activity involves two 
agonists, IL-1α and IL-1β, specific receptors, and a 
naturally occurring antagonist, IL-1Ra. Some of the 
most relevant properties of IL-1 biological activity 
are the ability to initiate cyclooxygenase type 2 and 
inducible nitric oxide, leading to substantial expression 
of prostaglandin E2 and nitric oxide by cells exposed to 
IL-1β. 
Moreover, IL-1β is able to determine lipolysis, 
glucose transport, and adipocyte maturation in adipose 
tissue, to inhibit lipogenesis, via the IL-1 receptor type 
1 and the IL-1 receptor accessory protein, like TNF-α. 
In obese individuals the serum level of IL-1Ra is 
up-regulated for a feedback down-regulation, resulting 
in an acquired resistance to leptin, rising the high 
values as in inflammatory autoimmune diseases and 
sepsis[86,87]. 
Polymorphisms affecting IL-1 production, like the 
SNP at IL-1β (+3954), the SNP at IL-1α (-889) and the 
SNP at IL-1α (+4845) are associated with increased 
levels of inflammatory mediators, and also with 
increased severity of several chronic diseases, including 
Alzheimer’s disease[88], periodontal disease and 
others. This proinflammatory IL-1 genotype pattern 
recently has been associated with cardiovascular acute 
coronary events. For example, despite having total 
cholesterol levels below 200 mg/dL, individuals who 
carried two copies of IL-1α (+4845) allele 2 were four 
times (P < 0.01) more likely to have a coronary heart 
disease event during an 11-y monitoring period than 
were individuals with the same level of cholesterol 
but who did not carry this IL-1 genotype (unpublished 
data, Interleukin Genetics, Waltham, MA, United States). 
The IL-1Ra antagonizes the effects of IL-1α and 
-1β[89], and the anti­inflammatory cytokine interferon­
beta and leptin can induce IL-1Ra production without 
increasing IL-1[86,90]. In subjects with hyperleptinemic 
obese individuals the serum sIL-1Ra levels are higher 
as compared to non obese subjects[91].
Furthermore, in subjects that underwent to in-
testinal bypass surgery, sIL-1Ra levels dropped after 
weight loss, correlating with BMI and the degree of 
insulin resistance better than with serum leptin levels, 
according to metabolic control unmediated by leptin.
GLUCOTOXICITY
The ability of the pancreatic alpha and beta cells to 
increase the uptake of glucose can be compromised by 
constant hyperglycemia, even mild. This mechanism, 
compromising the glucose transport mediated by 
insulin, prevents the possibility of self correction, and 
start a vicious cycle mechanism that leads to dete-
rioration of the metabolic process[92]. 
Continuous overstimulation of the beta-cell by 
glucose could eventually lead to depletion of insulin 
stores, worsening of hyperglycemia, and finally dete­
rioration of beta-cell function. 
The mechanisms responsible for changes of insulin 
sensitivity vs insulin resistance clearly vary and involve 
changes in both beta -cell function and beta -cell mass, 
although in most instances it appears that functional 
changes predominate. Moreover, the beta-cell must 
also alter its activity when this critical modulator 
changes for more prolonged periods[60].
Several mechanisms might explain the glucotoxicity 
due to prolonged hyperglycemia[93,94], such as beta -cell 
exhaustion, oxidative stress induced by free radical 
oxygen species, endoplasmic reticulum (ER) stress, 
inflammation caused by proinflammatory cytokines 
and chemokines, loss of neogenesis, proliferation of 
beta -cells, gradual loss of insulin gene expression and 
other beta­cell specific genes, changes in mitochondrial 
number, morphology and function, disruption in calcium 
homeostasis[95].
In the presence of hyperglycemia, prolonged 
exposure to increased free fatty acids result in accu-
mulation of toxic metabolites in the cells (“lipotoxicity”), 
finally causing decreased insulin gene expression and 
impairment of insulin secretion.
Chronic exposure to abnormally high blood glucose 
has detrimental effects on insulin synthesis/secretion, 
cell survival and insulin sensitivity through multiple 
mechanisms (“glucotoxicity”), which in turn lead to hyper-
glycemia and finally to the vicious circle of continuous 
deterioration of beta cell function[96].
Beta cells exposed to an increased insulin secretory 
request place a high demand on ER for the synthesis 
of proinsulin, leading to cellular stress[97]. 
Due to chronic ER stress and strong unfolded protein 
response, beta cell death through apoptosis (mediated 
by stress kinases and transcription factors) may be 
initiated. In addition to glucose, free fatty acids (FFA) 
and islet amyloid polypeptide are triggers of beta cell 
ER stress[98]. Moreover, reactive oxygen species (ROS), 
free radicals that are intermediate metabolites derived 
from oxygen metabolism in mitochondria, primarily due 
to hyperglycemia, causes oxidative stress in various 
tissues, playing an important role in both physiology and 
pathology in beta-cells. ROS are continuously produced 
by the mitochondrial electron transport system as a 
byproduct of the oxidative phosphorylation pathway; 
however, normal cells have antioxidant defenses to 
rapidly neutralize ROS and maintain an optimal redox 
potential for appropriate biological cell function[99]. This 
optimal redox balance is impaired because of increased 
ROS production and insufficient endogenous anti­oxidant 
defenses of the β-cells.
Chronic hyperglycemia leads to decreased number 
of mitochondria and changes of their morphology[99] in 
the β-cells. This is associated with impaired oxidative 
phosphorylation, decreased mitochondrial Ca2+ 
capacity and decline in ATP generation[100]. In addition, 
disruption in Ca2+ homeostasis (e.g., changes in 
glucose-induced Ca2+ influx, ER Ca2+ depletion) 
negatively impacts on beta cell growth/function and on 
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the insulin secretion pathway[101].
LIPOTOXICITY
When adipose tissue cannot meet the demand of 
storing excessive energy, triglyceride is accumulated in 
non-adipose tissues as ectopic fat, which may lead to 
insulin resistance in the liver and skeletal muscle and 
insufficient insulin secretion in the pancreas[48,102,103].
High plasma FFA and triglyceride levels lead to 
increased import of FFAs into non-adipose tissues (i.e., 
liver, muscle, pancreas), contributing to intracellular lipid 
accumulation. This phenomenon, known as lipotoxicity, 
may play an important role in the pathogenesis of 
diabetes and heart failure in humans[104]. 
Adverse consequences of lipid overload have been 
observed in many organ systems, mainly in the heart, 
skeletal muscle, pancreas, liver, and kidney[104].
In addition to primary hyperlipidemias, serum trigly-
cerides[105,106] and FFAs[107] are elevated in type 1 and 
type 2 diabetics and plasma FFA levels are elevated in 
obese individuals[108]. 
The cross-talk has been shown to affect the function 
of adipocytes, such as lipolysis, which will most 
likely result in an altered concentration of circulating 
free fatty acids. Indeed, obese persons have higher 
levels of free fatty acids in plasma compared to lean 
subjects[109-111].
Several indirect lines of evidence suggest that fatty 
acids, contained in the diet, can modulate the immune 
response. One of these is that levels of several fatty 
acids are associated with levels of inflammatory 
markers in healthy individuals[58]. 
The overall data suggest that low concentrations 
of fatty acids can influence the proliferation of T­cells, 
whereas higher concentrations induce apoptosis in a 
dose- dependent manner, through the induction of 
several pathways[112-117]. 
In addition, the concentration at which apoptosis 
occurs is also determined by the degree of saturation 
and the length of the fatty acid. While short-chain 
fatty acids are not toxic even at a concentration of 800 
mmol/L or higher[113], longer, and more unsaturated 
fatty acids can already be toxic in low concentrations 
(e.g., linoleic acids) is toxic at 100 mmol/L[114,115]. 
In contrast to the apoptotic effects, the modulatory 
effects of low, non-toxic concentrations of fatty acids on 
proliferation do not seem to correlate with length of the 
fatty acids tested. 
de Jong et al[59] conclude that, free fatty acids induce 
proliferation of resting T-cells in low concentrations, 
while higher concentrations induce apoptosis.
BODY FAT DISTRIBUTION ACROSS 
GENDER AND ETNICITY
Etiological contributing factors to VAT depot and 
distribution are represented by age, gender, genetics, 
and ethnicity[118].
Substantial anatomical differences between 
males, that accumulate adipose tissue in the upper 
body (trunk, abdomen), and females, with a usual 
accumulation of adipose tissue in the lower body (hips, 
thighs), are practically unique in human[119-121].
Vague[122] identified two different body shapes, 
proposing the two terms “android obesity”, to refer to 
adipose tissue accumulated preferentially in the trunk/
upper body area closely related to hypertension, CVD, 
gout, and diabetes, and the term “gynoid obesity” to 
refer to adipose tissue accumulation in the hips and 
thighs, with less associated complications[123,124].
Visceral fat depot, evaluated by MRI and computed 
tomography (CT), was found to be specifically asso-
ciated with the metabolic alterations related to obesity, 
both in men and women[125-127]; subcutaneous fat in 
general define a positive effect on insulin sensitivity[128]. 
Genetic predisposition could explain the fact that 
females, although high BMI, are protected against 
insulin resistance more than males[118]. Furthermore, 
the capacity to increase the fat depots depends on 
the ease with which local preadipocytes can be readily 
activated toward differentiation process[129].
Although ethnicity is a factor that determines the 
different adipose tissue distribution and responses to 
the cardiometabolic risks[118,130,131], as highlighted by 
Deurenberg et al[132], that observed ethnic differences 
in BMI at similar levels of PBF, in Chinese, Indonesian, 
and Thai populations respect to Caucasians (American, 
Australian, and European Whites analyzed as one 
group). Moreover, Asian Indians have more abdominal 
fat than Caucasians[133,134], and Caucasians have more 
VAT than African Americans[135-137]. On the other hand, 
in Asians and Indian Asians the accumulation of fat is 
mainly in the visceral area[131,138,139].
Genetic and epigenetic programming is one of the 
most credible explanations for the observed differences 
in the storage of lipid depot[118,139,140].
OBESITY: BODY COMPOSITION 
PHENOTYPES
Nowadays four phenotypes of obese individuals have 
been widely described (Table 1): (1) normal weight 
obese (NWO)[141]; (2) metabolically obese normal 
weight (MONW)[142,143]; (3) MHO; and (4) metabolically 
unhealthy obese (MUO) or “at risk” obese with MS[144].
The characteristic of the four obese phenotypes are 
depicted in Figure 2.
Moreover, the sarcopenic obesity has been charac-
terized, and related to all the described phenotypes[145]. 
Moreover the category of normal weight lean (NWL), 
represented by metabolically healthy normal weight 
(MHNW) has been classified to distinguish from NWO.
According to the causality and anatomic, patho-
physiologic, and clinical manifestations of obese 
phenotypes, we can define NWO and MHO belonging 
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Table 1  Obesity classification
Publication Year Definition
Normal weight obesity - NWO
De Lorenzo et al[141] 2005 Normal weight (by BMI) + PBF > 30 (dual X-ray absorptiometry) + ↓ lean body composition of the left leg. 
Do not have metabolic syndrome
Di Renzo et al[162] 2006 NWO syndrome is characterized by wild type homozygotes genotypes regarding IL-15 R-α and MTHFR 
677C/T polymorphism
De Lorenzo et al[147] 2007 ↑ concentrations of pro-inflammatory cytokines IL-1α, IL-1β, IL-6, IL-8, TNF-α in NWO respect to non obese 
group
Di Renzo et al[160] 2007 The allele 2 (A2) of IL-1 receptor antagonist (Ra) in NWO subjects was associated with ↑ of IL-1β plasma 
amount
Marques-Vidal et al[151] 2008 Normal weight (by BMI) + ↑PBF (Bioelectrical impedance) or fat mass index ≥ 8.3 kg/m2 (men) or ≥ 11.8 
kg/m2 (women)
Di Renzo et al[161] 2008 Genotyping of -175 G/C IL-6 polymorphism: in G/G the serum IL-6 level of NWO (10.70 ± 2.52 pg/mL) 
and obese (10.67 ± 1.09 pg/mL) was significantly higher compared with NWL women (5.54 ± 1.51 pg/mL). 
Positive correlation between PBF and plasma IL-6 and between HOMA-IR and plasma IL-6 only in NWO e 
obese G/G carrier
Marques-Vidal et al[149] 2010 ↑ blood pressure, ↑ lipid levels and ↑ prevalence of dyslipidaemia [OR = 1.90 (1.34-2.68)] and fasting 
hyperglycaemia [OR = 1.63 (1.10-2.42)] respect to lean women, whereas no differences were found between 
NWO and overweight women.
Di Renzo et al[159] 2010 ↓ glutathione and nitric oxide metabolites were significantly lower in pre-obese-obese and NWO compared 
to normal weight individuals. Lipid peroxide levels negatively correlated to FFM% and positively correlated 
to PBF, IL-15, TNF-α, insulin, total cholesterol, LDL, and triglycerides
Romero-Corral et al[157] 2010 NWO not manifest the metabolic syndrome, despite a cluster of metabolic and genetic features such as the 
higher prevalence of dyslipidemia, hypertension (men), CVD (women), and a 2.2-fold increased risk of CVD 
mortality (women) compared with those with low PBF
Kim et al[156] 2013 Normal weight (by BMI) + ↑ PBF
Madeira et al[155] 2013 Normal weight (by BMI < 25) + Sum of triceps and subscapular skinfolds > 90th percentiles
Di Renzo et al[164] 2013 G/A -308 TNF-α polymorphism contributes to sarcopenic obesity susceptibility in NWO
Di Renzo et al[165] 2014 TP53 codon 72 in exon 4 polymorphism was associated to the reduction of appendicular skeletal muscle 
mass index in NWO, leading to increase of sarcopenia risk
Oliveros et al[146] 2014 Normal BMI, ↑ PBF content and at increased risk for metabolic dysregulation, systemic inflammation and 
mortality
Jean et al[158] 2014 Highlight the importance of PBF correct assessment and body fat distribution in the clinical setting to 
identify NWO phenotype
Metabolically healty obese - MHO
Bonora et al[178] 1998 Subgroup of obese individuals with a normal metabolic response
Sims[179] 2001 The MHO subset include family members with uncomplicated obesity, early onset of the obesity, fasting 
plasma insulin within normal range, and normal distribution of the excess fat
Karelis et al[190] 2004 ↑ Fat mass + Normal Metabolic profile + ↑ insulin sensitivity
Karelis et al[143] 2005 Favorable inflammation profile: ↓ hsCRP, ↓ α-1 antitrypsin levels compared with insulin-resistant women, 
suggesting that lower inflammation state could play a role in the protection of this phenotype
Succurro et al[171] 2008 Respect to MONW, MHO have a healthier metabolic risk profile and ↑ disposition index (insulin sensitivity 
x insulin secretion)
Wildman et al[50] 2008 In NHANES sample, it was found a prevalence of 32% among obese adults over the age of 20
Arnlöv et al[192] 2010 MHO individuals were at an increased risk of major CVD events as compared to MHNW individuals in 
follow-up periods (> 15 yr)
Eshtiaghi et al[194] 2014 MHO phenotype over a 10 yr period progressed to frank metabolic syndrome
Achilike et al[196] 2015 Among subjects classified as MHO at baseline, almost half (47.6%) of them progressed to metabolically 
unhealthy obese (MUO) within the 7.8-yr follow-up period
Shaharyar et al[195] 2015 Both MHO individuals and MONW phenotypes were associated with ↑ high hsCRP, and hepatic steatosis
Metabolically obese but normal weight - MONW
Ruderman et al[166] 1981 Subtle increase in adiposity and/or hyperinsulinism creating obese associated diseases in normal weight (by 
standard weight tables)
Ruderman et al[167] 1998 CHD, T2DM and other disorders associated with obesity + normal weight (< 115% of ideal body weight or 
BMI < 28 kg/m2)
Dvorak et al[168] 1999 Impaired insulin sensitivity, BMI < 26.3 kg/m2 ↑ total fat mass (+20%), ↑ PBF (+16%) (dual x-ray 
absorptiometry), ↑ subcutaneous fat (+33%), ↑ visceral fat (+26%)
Esposito et al[176] 2004 ↑ inflammation biomarkers, TNF-α and IL-6, in as a result of the larger visceral fat areas in this group
Conus et al[169] 2004 Insulin sensitivity determined by HOMA > 1.69 with normal weight (by BMI < 25 kg/m2), ↑PBF (dual
X-ray absorptiometry), ↓ FFM, ↓ physical activity energy expenditure, ↓ peak oxygen uptake
Meigs et al[170] 2006 BMI < 25 kg/m2 + Metabolic Syndrome criteria/insulin resistance
Succurro et al[171] 2008 Normal weight (by BMI) + Impaired insulin sensitivity, ↑ visceral adiposity, ↓ HDL, ↑ fasting glucose, ↑ 
triglycerides, hypertension
Thomas et al[175] 2012 According magnetic resonance imaging, they refined MONW phenotype and renaming this sub-phenotype 
as “thin-on-the-outside fat-on-the-inside” (TOFI), with a higher ratio of visceral:subcutaneous abdominal 
adipose tissue
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to the category of “fat mass disease”, and MONW and 
at risk obesity to “sick fat disease”. Moreover, NWO 
women are quite different from MHO women and may 
also be distinguished from MONW women, according 
to fat distribution, inflammatory and metabolic para­
meters, and genetic variants.
NWO
The new concept of NWO had been proposed[141,146]. 
NWO subjects have normal BMI (18.5-24.9 kg/m2), 
and highest body fat percentage (BF%) (men, ≥ 
23.5%, women, ≥ 29.2%), associated at a higher 
degree of subclinical vascular inflammation and risk for 
cardiometabolic disease, of which body fat is a major 
contributing factor[147-149]. 
Worldwide prevalence of NWO is near to 10%, and 
the prevalence is higher in women than in men[150-152]. 
In women, prevalence of NWO increased considerably 
with age, and virtually all women aged over 55 with 
a BMI < 25 kg/m2 were actually considered as NWO. 
Even if the proportion of PBF changes with age and 
sex[23,153], using sex and age­specific thresholds for PBF 
led to a much lower prevalence of NWO in women, 
whereas little differences were found for men[15,20].
As demonstrated by Kang et al[154], NWO subjects 
highlighted a significantly higher blood pressure, 
fasting glucose level, and worse lipid profile compared 
to normal weight subjects, independently associated 
with elevated TBRmax values, that may determine and 
justify the metabolic and CVD occurring risks. 
Due to the peculiarity of the relationship between 
lean mass distribution (lean of the right part of the body 
trunk and of the left leg), and CVD risk indexes, NWO 
could be considered an additional metabolic subset of 
obesity[141,155,156].
They also do not manifest the MS, despite a cluster 
of metabolic and genetic features such as the higher 
prevalence of dyslipidemia, hypertension (men), 
CVD (women), and a 2.2-fold increased risk of CVD 
mortality (women) compared with those with low total 
body fat mass[157].
Jean et al[158] have provided three potential expla-
nations for why normal-weight central obesity is linked 
to increased mortality include the following: (1) the 
accumulation of abdominal visceral fat as manifested 
by an increased girth: there is a very strong association 
between WC and visceral adiposity and the excess 
adipose tissue in the abdominal cavity organs, which 
are a source of inflammation and insulin resistance; 
(2) the reduced amounts of subcutaneous fat in the 
legs, hips, and buttocks, known to be protective for 
CVD and with a favorable metabolic function; and 
(3) the limited muscle mass, because like in NWO, 
people with normal-weight central obesity may also 
have sarcopenic obesity since, in order to have normal 
weight in the setting of large amounts of visceral fat, 
they likely have limited amounts of muscle mass.
De Lorenzo et al[141] firstly described the NWO 
syndrome characterized by higher oxidative stress 
level[159], early inflammatory status[147] and few metabolic 
abnormalities. 
The presence of SNPs of triad inflammatory genes, 
characterizes the NWO syndrome.
In NWO syndrome, the IL-1Ra allele 2 increases 
the risk of ovarian, pancreatic, cervical and gastric 
cancer, probably due to increased IL-1 production and 
inhibition of gastric acid secretion[160].
According to the -174G/C promoter polymorphism 
of the IL-6 gene, G/G NWO showed a strong corre-
lation between HOMA-IR and PBF[161].
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Eckel et al[172] 2015 ↑ waist circumference (women: 75.5 cm vs 73.1 cm; men: 88.0 cm vs 85.1 cm), ↑ HbA1c (6.1% vs 5.3%), ↑ 
triglycerides (1.47 mmol/L vs 1.11 mmol/L), and ↑ hsCRP (0.81 mg/L vs 0.51 mg/L) , ↓ HDL (1.28 mmol/L 
vs 1.49 mmol/L) and ↓ adiponectin (6.32 μg/L vs 8.25 μg/mL)
Du et al[173] 2015 Lipid accumulation product and visceral adiposity index, two markers of visceral obesity, identify the 
MONW phenotype
Metabolically unhealthy obese - MUO
Alberti et al[201] 2005 MUO subjects are characterized by a BMI ≥ 30 kg/m2, a PBF > 30% and high visceral fat mass, closely linked 
to the development of the metabolic syndrome, T2DM, and atherosclerotic cardiovascular disease
Fabbrini et al[47] 2009 In MAO subjects, but not MNO subjects, moderate weight exacerbated several metabolic risk factors for 
CVD: ↑ blood pressure, ↑ plasma triglyceride,↑ in intra hepatic triglyceride, ↑ VLDL apoB100 and ↓ plasma 
adiponectin concentrations and insulin sensitivity in the liver, skeletal muscle, and adipose tissues, ↓ adipose 
tissue expression of genes involved in glucose uptake and lipogenesis
O'Connell et al[210] 2010 MUO and obese with T2DM subjects had a omental adipocyte size greater than MHO, moreover MUO 
group had an intermediate degree of steatosis (43%) respect to MHO (3%) and obese with T2DM (74%).
Di Daniele et al[202] 2013 6 mo of dietary intervention based on Italian Mediterranean Diet in “at risk” obese subjects, determined 
a reduction (-52%) in the prevalence of the metabolic syndrome and a reduction in terms of waist 
circumference, BMI and total body weight.
Calanna et al[211] 2013 At-risk obese individuals showed ↑ plasma glucose dependent insulinotropic polypeptide, ↓ post-glucose 
load glucagone-like-peptide-1, and ↑ levels at baseline and after glucose load, indicating inappropriate 
glucagone suppression
BMI: Body mass index; PBF: Percentage of total body fat; NWO: Normal weight obesity; NWL: Normal weight lean; FFM: Fat free mass; HOMA: 
Homeostatic model assessment; LDL: Low density lipoprotein; HDL: High density lipoprotein; CVD: Cardiovascular disease; MHO: Metabolically healthy 
obese; HbA1c: Glycated haemoglobin; hsCRP: High sensitive C-reactive protein; MHNW: Metabolically healthy normal weight; MONW: Metabolically 
obese normal weight; MUO: Metabolically unhealthy obese; CHD: Chronic heart disease; T2DM: Type 2 diabetes mellitus; MAO: Metabolic abnormal 
obese; MNO: Metabolically normal obese. 
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Moreover, NWO are characterized by a wild type 
homozygotes genotypes regarding IL-15 receptor-alpha 
and methylenetetrahydrofolate reductase (MTHFR) 
enzyme[162], suggesting a “conversation” between 
adipose tissue and skeletal muscle[163].
The importance of the TNF-α gene polymorphism 
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27.9 ± 4.6[147] 32.3-3.33[191] 22.5 ± 2.0[168] 22.6 ± 1.9[147] 19.2 ± 1.5[147] BMI (kg/m2)
  85.8 ± 10.2[147] 101.9-105.3[191] 77.5 ± 0.3[174] 72.3 ± 4.9[147] 65.1 ± 3.9[147] Waist (cm)
42.9 ± 7.3[147]    38.3 ± 18.5[171] 31.8 ± 5.9[168] 34.9 ± 5.0[147] 23.3 ± 2.2[147] Fat mass (%)
    5.4 ± 0.11[147] 4.90-5.05[191]   4.4 ± 0.4[168]     5.1 ± 0.16[147]   5.20 ± 0.18[147] Glucose (mmol/L)
  5.65 ± 0.63[147] 4.80-5.16[191]   5.3 ± 0.9[168]   4.87 ± 0.67[147]   4.60 ± 0.45[147] Total cholesterol (mmol/L)
  1.82 ± 0.51[147] 1.39-1.49[191]   1.7 ± 0.5[168]   1.76 ± 0.32[147]   1.79 ± 0.17[147] High-density lipoprotein (mmol/L)
  3.00 ± 0.91[147] 2.89-3.18[191]   3.1 ± 0.9[168]   2.69 ± 0.63[147]   2.77 ± 0.90[147] Low-density lipoprotein (mmol/L)
  1.26 ± 0.19[147] 1.03-1.24[191]   2.4 ± 0.7[168]   0.97 ± 0.16[147]   0.75 ± 0.12[147] Triglycerides (mmol/L)
63.2 ± 7.6[147] 61.8-66.6[191]   60 ± 20[168]   44.4 ± 12.5[147] 45.8 ± 9.7[147] Insuline (pmol/L)
- 0.8-2.7[195] 0.6-2.2[195] - 0.5-1.6[195] hs-CRP (mg/L)
MUO MHO MONW NWO NWL
BMI (kg/m2)  22.4-22.7[191] 24.1 ± 0.7[156]    22.87 ± 0.07[174] 32.3-33.3[191]   31.59 ± 0.74[203]
Waist (cm)  83.8-85.2[191] 89.4 ± 1.6[156]    82.5 ± 0.3[174] 108.3-112.1[191]  108 ± 7[172]
Fat mass (%)    19.4 ± 0.2[174] 26.4 ± 1.3[156]    22.3 ± 0.2[174]   31.1 ± 3.4[181]   26.44 ± 0.53[203]
Glucose (mmol/L)  5.1-5.2[191]   2.53 ± 0.19[156]     5.38 ± 0.02[174] 5.1-5.3[191]     5.44 ± 0.10[203]
Total cholesterol (mmol/L)  4.8-5.0[191]   5.09 ± 0.72[156]     5.08 ± 0.04[174] 4.8-5.2[191]     5.11 ± 0.99[203]
High-density lipoprotein (mmol/L)  1.3-1.4[191]   1.23 ± 0.24[156]     1.18 ± 0.01[174] 1.2-1.3[191]     1.23 ± 0.36[203]
Low-density lipoprotein (mmol/L)  4.8-5.0[191]   3.09 ± 0.62[156]     2.73 ± 0.04[174] 4.8-5.2[191]     3.20 ± 0.94[203]
Triglycerides (mmol/L)  1.1-1.3[191]   3.84 ± 1.77[156]  2.47-2.64[174] 1.2-1.4[191]     1.86 ± 0.19[203]
Insuline (pmol/L)  44.5-48.1[191]   42.3 ± 19.4[156]  52.8-55.8[174] 63.1-73.2[191]   16.37 ± 1.76[203]
hs-CRP (mg/L)  0.5-1.6[195] -  0.6-2.2[195] 0.8-2.7[195] -
NWL NWO MONW MHO MUO
Figure 2  Characteristic of the four obese phenotypes. A: Women; B: Men. NWO: Normal weight obese; MONW: metabolically obese normal weight; MHO: 
metabolically healthy obese; MUO: metabolically unhealthy obese; BMI: body mass index; hsP: High-sensitive C-reactive protein. Data are expressed as average ± 
SD (a ± b), or as minimum-maximum (a-b), according to the references.
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to total body lean mass variation in NWO syndrome, 
demonstrating that G/A -308 TNF-α polymorphism 
contributes to sarcopenic obesity susceptibility[164]. 
TP53 codon 72 in exon 4 polymorphism was associated 
to the reduction of appendicular skeletal muscle mass 
index (ASMMI) in NWO, leading to increase of sarcopenia 
risk[165].
This finding gives much more support to the idea 
that a genetic approach could be predictive for finding 
a vulnerable category of people[160-162,164].
MONW
MONW subjects, first described and revisited by 
Ruderman et al[166,167], represents a subset of persons 
who have a normal weight and normal BMI but have a 
cluster of metabolic characteristics that may increase 
the possibility of developing the MS. 
MONW women, also defined as “metabolically 
unhealthy normal weight” (MUNW) have metabolic distur-
bances typical of obese persons and are characterized by 
having a high amount of visceral fat, a low BMI, a high 
fat mass, a low lean body mass, low insulin sensitivity, 
and high triacylglycerol concentrations, premature 
chronic degenerative disease and liver fat[168-171].
In a recent paper Eckel et al[172] found that, MUNW 
individuals were characterized by known diabetes 
risk factors, e.g., they were significantly more likely 
to be male, former smokers, hypertensive, and 
less physically active compared to normal weight 
individuals without incident diabetes. Higher WC 
(women: 75.5 cm vs 73.1 cm; men: 88.0 cm vs 85.1 
cm), higher HbA1c (6.1% vs 5.3%), higher triglycerides 
(1.47 mmol/L vs 1.11 mmol/L), and higher levels of 
high sensitive C-reactive protein (0.81 mg/L vs 0.51 
mg/L) as well as lower levels of HDL-cholesterol (1.28 
mmol/L vs 1.49 mmol/L) and adiponectin (6.32 μg/mL 
vs 8.25 μg/mL) characterized this phenotype. 
Moreover, lipid accumulation product (LAP) and 
visceral adiposity index, two markers of visceral 
obesity, identify the MONW phenotype[173].
Lee et al[174] recently found that in MONW indivi-
duals, the triglycerides index [(fasting triglycerides 
(mg/dL) × fasting glucose (mg/dL)/2)] was higher 
respect to normal weight population, managing to 
clearly discriminate individuals at metabolic risk from 
NWL subjects.
Thomas et al[175] refined MONW phenotype using 
MRI, showing a disproportionate deposition of VAT 
respect to overweight or obese subjects; they called 
this sub-phenotype, “thin-on-the-outside fat-on-the-
inside” (TOFI).
TOFI subjects showed a higher ratio of visceral:
subcutaneous abdominal adipose tissue, and it was 
been observed in both male and female subjects and it 
was accompanied by increased levels of both liver and 
muscle fat[175].
Higher concentrations of inflammation biomarkers, 
TNF-α and IL-6, in the MONW group could be the result 
of the larger visceral fat areas in this group, supporting 
the correlation between visceral fat and both insulin 
resistance and CVD[176].
However, in different population, CRP levels were 
significantly higher in MONW women than in the 
control group, and serum IL-6, IL-18 levels in males 
and females did not differ in both groups[177].
MHO
MHO is a new concept in which an individual may 
exhibit an obese phenotype in the absence of any 
metabolic abnormalities[178,179].
MHO persons, despite having excess of body fat, 
have a metabolic profile characterized by high insulin 
sensitivity, a favorable lipid profile, and no sign of 
hypertension[144].
However, there is no consensus as to how metabolic 
normality should be defined, so the reported prevalence 
of MHO ranges from 2% to 50%, depending on the 
specific criteria used and the population studied[50,180-189].
MHO subjects when compared with obese insulin 
resistant adults have a healthier metabolic risk profile 
and higher disposition index (insulin sensitivity X 
insulin secretion)[171].
According to Karelis et al[190], the selection criteria 
for MHO individuals were partially based on the National 
Cholesterol Education Program’s Adult Treatment Panel 
Ⅲ report for lipid profiles [triglycerides: < 1.7 mmol/L, 
total cholesterol: < 5.2 mmol/L, HDL-cholesterol: > 1.3 
mmol/L and low-density lipoprotein (LDL)-cholesterol: 
< 2.6 mmol/L] and from the study of Brochu et al[187] 
for insulin sensitivity (HOMA < 1.95); when 4 out of 5 
criteria are met, the diagnosis of the MHO individual 
could be made. Intrahepatic triglyceride (IHTG) content 
and VAT volume were much higher in metabolically 
abnormal obese subjects than in MHO subjects.
In 2005 Karelis et al[143] indicated that postmeno-
pausal women displaying the MHO phenotype also 
have a favorable inflammation profile, as shown by 
lower CRP and α-1 antitrypsin levels compared with 
insulin­resistant women, suggesting that lower inflam­
mation state could play a role in the protection of this 
phenotype.
Manu et al[191] found that MHO was similar to NWL 
group regarding terms of age, fasting glucose and 
triglyceride levels, but with higher insulin resistance, 
C-reactive protein levels, LDL cholesterol levels levels 
and systolic blood pressure, and lower intake of dietary 
fiber and levels of physical activity.
However, studies with longer follow-up periods (> 
15 years) have demonstrated that MHO individuals 
were at an increased risk of major CVD events as 
compared to MHNW individuals[192,193].
Examining the natural history of the MHO phe-
notype it has been showed that over half of subjects 
progressed to frank MS over a 10 years period[194]. 
Moreover, Shaharyar et al[195] demonstrated that 
both MHO individuals and MONW phenotypes were 
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associated with elevated hs-CRP, and hepatic steatosis.
In a recent paper, Achilike et al[196] showed that 
among subjects classified as MHO at baseline, almost 
half (47.6%) of them progressed to MUO within 
the 7.8-year follow-up period. MHO individuals who 
developed MUO were older and had more adiposity, 
higher 10-year CHD risk and lower HDL cholesterol 
than those who remained as MHO or become non-
obese. They conclude that, MHO may not be a stable 
condition, because it confers markedly increased risk 
of developing multiple metabolic abnormalities in the 
future.
According to the editorial comment of Puri[197], it 
must be simply accepted that obesity is a disease, and 
no level of obesity can be considered healthy. In fact, 
the studies by Chang et al[198], demonstrated that, on 
the basis of the coronary artery calcium scores, MHO 
had a significantly greater prevalence of coronary 
atherosclerosis than the metabolically-healthy but 
normal weight subjects. Moreover, Kramer et al[199] 
observed that compared with NWL subjects, MHO were 
at significantly greater risk for death and cardiovascular 
events.
All these data raised serious doubts on the concept 
of obese people maintaining a benign prognosis and 
highlight the fact that obesity per se is a genuine 
disease[197].
Therefore, both MHO and MONW phenotypes, in the 
same manner of “at risk obese” phenotype, may not be 
benign and physicians should strive to treat individuals 
in these subgroups to reverse these conditions.
MUO
The MUO, also defined as “at risk” obese subjects 
are characterized by a BMI ≥ 30 kg/m2, a PBF > 
30% and high visceral fat mass, closely linked to the 
development of the MS, T2DM, and atherosclerotic 
CVD[200-203].
Although a unifying definition of the MS does not 
exist[204-206], there is a worldwide agreement about 
the role of insulin resistance and abdominal obesity 
as the main pathophysiological mechanisms for the 
development of metabolic disorders characterizing the 
MS[207,208].
Hormonal differences after an oral glucose tolerance 
test may explain the propensity for impaired glucose 
homeostasis in then “at-risk” obese phenotype[209]. 
O’Connell et al[210] divided the obese subjects in 
three class: MHO, MUO and obese with DM. They 
found that MUO and T2DM obese subjects had an 
omental adipocyte size greater than MHO, while 
subcutaneous adipocyte size, was related to metabolic 
health, and possibly progression from hepatic steatosis 
to fibrosis. Moreover, they showed that MUO group had 
an intermediate degree of steatosis (43%) respect to 
MHO (3%) and obese with T2DM (74%). Finally, they 
suggested that the size of the individual’s adipocytes is 
more important than the size of the individual.
MUO individuals showed higher plasma glucose 
dependent insulinotropic polypeptide, lower post-
glucose load glucagone-like-peptide-1, and higher 
levels at baseline and after glucose load, indicating 
inappropriate glucagone suppression[211].
Many studies have demonstrated that increased 
IHTG content (i.e., NAFLD) is a robust marker of 
metabolic dysfunction in obese people[47,212,213], and the 
amount of IHTG is directly correlated with the degree 
of insulin resistance in the liver, skeletal muscle, and 
adipose tissue[214]. 
However, not all obese persons develop NAFLD, 
insulin resistance, and cardiometabolic disease. A sub-
group of obese people are those have increased IHTG 
content are the “Metabolic Abnormal Obese” (MAO)[47].
Roberts et al[215] and others[216-219] have found that, 
compared with Metabolic Normal Obese (MNO) subjects, 
MAO have decreased adipose tissue expression of genes 
involved in glucose uptake and lipogenesis[47].
Moreover, Fabbrini et al[47] demonstrated distinct 
differences in the response to weight gain in MNO 
and MAO subjects. In MAO subjects, but not MNO 
subjects, moderate weight gain exacerbated several 
metabolic risk factors for CVD, including increased blood 
pressure, plasma triglyceride levels, VLDL apoB100 
concentrations, and VLDL apoB100 secretion rates, 
and decreased plasma adiponectin concentrations 
and insulin sensitivity in the liver, skeletal muscle, and 
adipose tissues. Weight gain also caused a greater 
absolute, but not relative, increase in intra hepatic 
triglyceride content in MAO subjects compared with that 
seen in MNO subjects. Together, these data suggest that 
increased adipose tissue capacity for lipogenesis helps 
protect against the adverse metabolic effects of weight 
gain.
In general, metabolic disorders are associated 
more strongly with visceral adiposity, rather than with 
subcutaneous adiposity; also, the anatomic location 
of VAT means that fatty acids are released directly 
into the portal circulation and fat accumulation in the 
liver has been shown to be an important feature of the 
MS[220,221].
SARCOPENIC OBESITY
Sarcopenia is defined as a loss of muscle mass 
leading to muscle weakness, limited mobility, and 
increased susceptibility to injury; an understanding of 
the underlying causes of muscle loss is critical for the 
development of strategies and therapies to preserve 
muscle mass and function[222]. 
It is well known that muscle is a type of endocrine 
organ, and excess fat mass exerts harmful effects 
on vascular inflammation BMI can miscategorize a 
significant proportion of subjects who have lower 
muscle mass content and higher body fat levels as 
those having a same cardiovascular risk as healthy, 
non-obese subjects[17].
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Moreover, according to PBF cut-off classification, 
Di Renzo et al[165] found that 14.68% of individuals 
were affected by sarcopenic obesity (81.25% NWO 
and 18.75% MHO/at risk obese, respectively), and, 
according to the population attributable risk (PAR), the 
sarcopenia incidence could be reduced at least of 20%, 
by appropriate detection and treatment of obesity.
The combination of sarcopenia and obesity[223,224], 
defined as sarcopenic obesity, is an important public 
health associated with functional limitations and 
increased mortality[225,226]. 
The concept of sarcopenic obesity was firstly 
proposed by Roubenoff who suggested how the 
inflammatory cytokines, produced by adipose tissue, 
especially visceral fat, can accelerate muscle catabolism 
and thus contribute to the vicious cycle that initiates 
and sustains sarcopenic obesity[145].
These cytokines have effects on the brain, liver, 
and pancreas that drive appetite, carbohydrate and fat 
metabolism, and energy balance. Thus, an increase 
in fat mass causes higher cytokines levels, which can 
affect protein metabolism both directly, via its effect on 
muscle amino acid balance, and indirectly, via insulin 
sensitivity.
Schrager et al[227], showed that components of 
sarcopenic obesity were associated with elevated levels 
of IL-6, C-reactive protein, IL-1 receptor antagonist, 
and soluble IL-6 receptor. They suggest that global 
obesity and, to a greater extent, central obesity directly 
affect inflammation, which in turn negatively affects 
muscle strength, contributing to the development 
and progression of sarcopenic obesity. These results 
suggest that proinflammatory cytokines may be critical 
in both the development and progression of sarcopenic 
obesity.
The key problem for this disease is the diagnosis. 
For this reason, in order to avoid the risk of sarcopenic 
obesity, the diagnosis of obesity requires the utilization of 
various methods, including body composition evaluation, 
metabolic, functional and a genetic approach[17,228,229]. 
The assessment of the physical status in association 
with genotype represents a very important information 
to evaluate both the health status and quality of life. 
Moreover, while a number of risk factors and diagnostic 
methodologies are available, it would be very useful to 
be able to develop additional predictive tools and risk 
indexes for this pathology.
Among various methods using to assess body 
composition, DXA-derived total body fat mass, total 
body lean mass and ASMMI measures can reflect 
both the PBF, than muscle mass and muscle strength, 
providing a reliable measure for assessment of sarco-
penia and obesity[15,19,230].
More significant deviations from normal healthy 
body composition trajectories configure the develop-
ment of abnormal phenotypes such as high adiposity[41], 
low muscle mass, or a combination of the two[231].
For this reason, as highlighted by Prado et al[232], 
there is a need to detect the high adiposity with low 
muscle mass phenotypes at younger ages in order to 
carry out timely personalized treatment interventions, 
in which weigh loss strategies are aimed to increase or 
preserve muscle mass and reduce fat mass.
For this reason measurement of body composition 
are fundamental for individual risk stratification.
BODY COMPOSITION EvALUATION FOR 
BARIATRIC SURGERY
The success rates of suggested obesity prevention and 
treatment strategies including lifestyle modification, 
behavioral therapy, and pharmacotherapy are dis-
satisfactory and lack efficacy in the management of 
morbid obesity[233]. 
Surgery for the treatment of severe obesity is 
gaining increasing favor, an surgical interventions are 
currently the most effective evidence-based approach 
towards clinically significant and sustainable weight 
loss along with reduction in mortality and obesity-
related comorbidities[234,235].
According to the different classification of obesity 
subtypes, it is important to choose as the selection 
criteria of the subjects that may be underwent to 
bariatric surgery both the PBF, the distribution of 
adipose tissue and the metabolic variables.
Bariatric surgery, included Roux-en-Y gastric 
bypass (RYGB), laparoscopic adjustable gastric band 
(LB), duodenal switch, and sleeve gastrectomy[236-238], 
has proven to be a treatment of choice for morbid 
obesity[234,239], and it is recommended for patients 
with BMI above 40 kg/m2 or higher than 35 kg/m2 
when associated with comorbidities which include the 
different components of MS and type 2 diabetes[240].
As previously described, the expansion of adipose 
tissue lead to inflammation, hypoxia, insulin resistance, 
limitations on energy storage, net increase in circulating 
free fatty acids, lipotoxicity, adverse endocrine and 
immune responses. 
For example, in order to reduce serious sleep 
apnea, immobility, CVD and other medical disorders, 
obese patients with pathological obesity may undergo 
surgical treatments interventions, to reduce the 
adipose tissue[241].
Thus, a reduction in fat cell size and reduction in 
adipose tissue growth beyond its vascular supply are 
favorable effects that at least partially explain the 
observed reduction in inflammatory markers with a 
reduction in adiposity, occurs with bariatric surgery.
Reversion of the low-grade inflammation and of 
risk factors seem to occur when a reduction in BMI 
is achieved and loss of adipose tissue is observed in 
obese individuals, after LAGB[241,242].
As previously described the different adipose tissue 
depots may contribute differently to obesity related 
comorbidities, most studies have focused on VAT 
and SAT findings from a single abdominal slice, as an 
appropriate surrogate measure of total VAT and total 
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SAT.
However, Weiss et al[243] reported that the ratio 
between VAT and SAT remains fairly constant 6 mo 
following bariatric. In fact, they observed a weight 
reduction of 47% in male and 42.6% in female 
subjects, with a reduction of VAT and total SAT of 35% 
and 32%, respectively, in both sexes.
Weight loss after bariatric surgery is usually asso-
ciated with an improvement in insulin resistance[244]. 
Most studies have demonstrated a strong asso-
ciation between VAT and insulin resistance[245]. In one 
study, reduction in VAT was associated with improve-
ment in oral glucose tolerance even after adjusting 
for overall weight loss[246], even if it is unclear whether 
greater VAT is a marker of insulin resistance or plays a 
causal role[247]. 
Moreover, insulin sensitivity correlated with gene-
ralized and regional adiposity, however, the magnitude 
of improvement in insulin sensitivity was predicted by 
the percent decrease in VAT, but not by other changes 
in body composition[248]. 
Data from Carroll et al[249] indicated that 6 mo after 
LGBS there were significant improvements in many 
cardiovascular and metabolic risk markers, with a 
major decreasing in insulin resistance associated to 
VAT reduction. The calculated total VAT volume (by 
CT) from eight abdominal slices decreased by 22% 
at 6 mo post-LB surgery, and the reduction in VAT 
was significantly correlated with reductions in insulin, 
HOMA, and glucose.
Korner et al[250], using whole-body MRI in post-
surgery weight-stable female patients (at 19-25 mo 
post-LB and RYGB surgery), found that in women post-
surgery, VAT was 44% less than in control subjects, and 
the difference remained significant after adjustment for 
total adipose tissue (TAT) and menopausal status. After 
adjustment for TAT, SAT in women post-surgery was 
significantly greater than matched controls, and there 
was a significant negative correlation of VAT and the 
degree of weight loss in women but this relationship 
was not significant in men. 
In fact, VAT was nearly identical in men post-
surgery compared with matched controls even though 
the degree of weight reduction was not significantly 
different from women (27.4% vs 32.6%).
Interestingly Toro-Ramos et al[251] showed that 
bariatric surgery caused substantial and robust loss 
in total and regional adipose tissue at 12 and 24 mo 
postbariatric surgery, with continued losses between 
12 and 24 mo in women, when body weight change 
was not significant. These results indicate that bariatric 
surgery has an important effect on reducing adipose 
tissue depots even after body weight has begun to 
stabilize. They found a remarkable 77% reduction in 
VAT at 12 mo postsurgery in both men and women. 
Weight loss obtained after bariatric surgery is 
associated with a highly significant reduction in cardio­
vascular risk factors[252,253]. Moreover, systematic review 
and meta-analysis reported complete resolution of 
T2DM in high percentage of the cases[239], and the rank 
order of increasing efficacy of the most common surgical 
procedures progresses from the purely restrictive to the 
mostly restrictive to the mostly malabsorptive. 
Surgical treatment of massive obesity is being 
extended to adolescents, seemingly with similar success 
and risk rates as in adults[254].
Pontiroli et al[237] have previous observed that, 
although LAGB induces a durable weight loss in morbidly 
obese patients, a significant proportion of these patients 
(25%) had a relatively modest weight loss.
It is not clear demonstrated whether genetic factors 
that play an important role in body weight homeostasis 
may account for the differences in the therapeutic 
effects of bariatric surgery. However, in literature 
there are some evidences that reported a relationship 
between -174G>C IL-6 polymorphism with diabetes, 
insulin resistance, MS, longevity and cardiovascular 
risk[255-257].
Di Renzo et al[258] evaluated the efficacy of LAGB 
surgery and the effects on anthropometry, body 
composition, fluid distribution, some cardiometabolic 
parameters and IL-6 plasma levels of selected patients 
after 6 mo follow-up, according to 174G>C IL-6 poly-
morphism. The authors have shown that in obesity 
bariatric treatment, LAGB seemed to determine a 
weight loss, sparing muscle mass and causing only 
mild body fluid alterations. The loss of fat mass was 
significant, despite a slight proportional loss of lean 
mass. Moreover, for the first time, this study has 
provided evidence that, the promoter polymorphism 
of IL-6 (-174G>C) gene is associated both with body 
composition and fluid distribution, in obese subjects, at 
baseline and at 6-mo follow-up after LAGB. C (-) obese 
carrier showed a lower capability to lose weight and 
body fat mass after LAGB, and a higher LAGB induced 
detrimental effect on bone density. This implies that 
LAGB was less effective if the subjects were carrying 
risk genotypes (C-carriers) for obesity[258].
In conclusion, it is possible suggest that an 
accurate and complete body composition evaluation 
together with genetic variations analysis would be 
a important tools for the selection of the type of the 
bariatric surgery, and for screening in order to predict 
therapeutic response of obese subjects, in terms of 
fat loss. Further studies of the court must be made to 
understand what is the best type of bariatric surgery, 
depending on the pathology. 
Remains the undoubted value of the assessment 
of body composition in obese patient whose treatment 
of bariatric surgery is recommended, in the control of 
quality and effectiveness of the intervention, ensuring 
patient safety. 
CONCLUSION
It is crucial, therefore, to recommend a bariatric 
surgery independently from BMI and body size, but 
taking into account adiposopathy and sick fat that 
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occurs with the expansion of body fat mass, changing 
the inflammatory and metabolic profile of the patient.
Interactions between genetic and environmental 
factors such as diet and lifestyle, particularly over-
nutrition and sedentary behavior, promote the progres-
sion and pathogenesis of polygenic diet-related diseases.
In the different obese phenotype, it is of primary 
importance to highlight a potential connection between 
body composition (as weight, body lean mass, body 
fat mass), and genetic variants, to identify individuals, 
who were at increased risk of reduction of skeletal 
muscle mass, that could lead to sarcopenic obesity. 
The highlighted findings underline that it is critical 
to assess body composition evaluation, looking to 
body fat mass and lean mass, and to identify a useful 
biomarker for selecting the population at risk for 
adipose tissue­associated inflammation, for preventive 
medicine purposes.
In this context, the mounting influx of global quan­
titative data from body composition, blood biomarkers, 
and genetic led to change the healthcare system, 
transforming of the concept of medicine, intended not 
only as a curative intervention but as a proactive P4 
medicine, that is predictive, preventive, personalized, 
and participatory[259].
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